Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novo Nordisk receives FDA approval for basal insulin Awiqli
The clinical trials assessed once-weekly Awiqli with mealtime insulin, oral anti-diabetic agents, and GLP-1 receptor agonists. Credit: Andrzej Rostek / Shutterstock.com.
The clinical trials assessed once-weekly Awiqli with mealtime insulin, oral anti-diabetic agents, and GLP-1 receptor agonists. Credit: Andrzej Rostek / Shutterstock.com.